Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds
Draft Report From Pricing Watchdog Calls Out Wegovy, Saxenda
Jul 18 2022
•
By
Jessica Merrill
A ICER report is taking a closer look at obesity drug prices • Source: Alamy
More from Drug Pricing
More from Scrip